Search

Displaying results 1511 - 1520 of 10000 in total
  1. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  2. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    pathways [A35558] and remains catalytically inactive due to structural modification [A35518]. … It was developed by Portola Pharmaceuticals and was approved in in May 2018.

  3. Drug

    Buformin

    go.drugbank.com/drugs/DB04830
    ApprovedWithdrawn

    It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.

    Categories: Drugs Used in Diabetes
  4. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    [L45768] The most common type of non-Hodgkin lymphoma,[L45763] DLBCL is relatively sensitive to chemotherapy and generally responsive to first-line treatment regimens like CHOP ([cyclophosphamide], [doxorubicin … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  5. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  6. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively

  7. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

    Mixtures: ILOTICINA DUO SOLUCION TOPICA, ILOTICINA DUO SOLUCION TOPICACategories: Retinoids for Topical Use in Acne
  8. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

  9. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.

  10. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

    International brands: Diu-Hydrin